Author:
Lessing Charon,Ashton Toni,Davis Peter
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Health Policy,Pshychiatric Mental Health
Reference47 articles.
1. Almond, S. et al. (2004) Relapse in schizophrenia: Costs, clinical outcomes and quality of life. British Journal of Psychiatry, 184, 346–351.
2. Babar, Z. U., Grover, P., Stewart, J., Hogg, M., Short, L., Seo, H. G., Rew, A. (2011). Evaluating pharmacists’ views, knowledge, and perception regarding generic medicines in New Zealand. Research in Social & Administrative Pharmacy: RSAP, 7(3), 294–305. doi: 10.1016/j.sapharm.2010.06.004 .
3. Baser, O., Palmer, L., & Stephenson, J. (2008). The estimation power of alternative comorbidity indices. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 11(5), 946–955. doi: 10.1111/j.1524-4733.2008.00343.x .
4. Boonleang, J., Pipatrattanaseree, W., Tanthana, C., & Mahatthanatrakul, W. (2010) Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. Clinical Therapeutics 32(10)1842–1853. doi: 10.1016/j.clinthera.2010.09.013 .
5. British, M. A., & Pharmaceutical Society of, G. B. (2014). British national formulary. London: British Medical Association: Royal Pharmaceutical Society of Great Britain 1966.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献